INTRODUCTION

*Naegleria fowleri* is a free-living amoeba that can survive in soil and warm fresh water [1]. When humans are exposed to contaminated water, amoeba enters the nasal cavity of the host and travels through the nasal mucosa, followed by moving along the cribiform plate and olfactory nerve, finally reaching the olfactory bulbs. Consequently, it destroys the central nervous system (CNS), thereby causing primary amebic meningoencephalitis (PAM) [2]. Although the infection is rare, it is fatal. To date, there have been only 7 cases reported in China, and none of them survived because of a severe increase of cerebrospinal fluid (CSF) and intracranial pressure.

CASE RECORD

A 43-year-old, previously healthy male, visited the emergency department of Zhejiang Provincial People’s Hospital, Hangzhou, China, on 20 August 20, 2016, with a 2-day history of persistently occipital headache, fever, myalgia, and fatigue. He was a tourist from Shenzhen, China, which is a large city located in southern China. Before visiting the Hospital, he had self-administered some NSAIDs (non-steroidal anti-inflammatory drugs) without achieving any relief. The headache was excruciating and intolerable.

At the time of Hospital admission, his vital signs were as follows: temperature, 39.1°C; pulse, 89 beats/min; respiratory rate, 33 breaths/min; blood pressure, 133/56 mmHg. Physical examination revealed the presence of positive meningeal irritation sign and left Babinski sign, while the CT scan of the head was normal. The routine blood test showed the leucocyte count of 10,480 cells/mm$^3$ with 80% neutrophils and C-reactive protein (CRP) of 2.6 mg/L. Then, lumbar puncture was dispensed, the CSF was turbid with high pressure (300 mmHg), positive Pandy’s test, very low level of glucose (< 1 mmol/L), highly elevated leukocytes (1,170 cells/mm$^3$ with 83% neutrophils) and protein (> 300 mg/dl). According to the above results, the patient was diagnosed with bacterial meningitis and administered empirical treatment. On August 21, he was intubated and sedated because of tachypnea and agitation, and then, transferred to the intensive care unit (ICU).

Considering the possibility of pyogenic meningitis, he was treated with 2 g meropenem every 8 hr, 600 mg linezolid every 12 hr intravenously, as well as, mannitol and dexamethasone. On the second evening of ICU stay, he suddenly developed a decreased responsiveness; the pupillary examination revealed the presence of fixed and dilated pupils. Thus, a 150 ml of 20% mannitol was infused for 30 min, followed by CT scan-
The brain CT scan demonstrated hydrocephalus, brain swelling, hyperdense interhemispheric fissure cistern, and supra sella cistern sign that confirmed cerebral hernia and meningoencephalitis. Subsequently, the external ventricular drainage was placed, and CSF samples were collected and re-examined. On August 24, he was eventually diagnosed with PAM as the trophozoites of *N. fowleri* were identified in the CSF via Wright-Giemsa staining (Fig. 1) and positive amplicons were obtained from the PCR for *Naegleria* spp. and *N. fowleri* with amplification fragment lengths of about 410 bp and 310 bp, respectively (Fig. 2). His family members recollected that he had been to a water park 5 days (5d) before the onset of symptoms. Then linezolid was discontinued immediately, and regime consisting of intravenous conventional amphotericin B (5 mg initial dose followed by 10 mg on day 2, 25 mg on day 3, and 50 mg/day thereafter) and fluconazole (400 mg/day) was begun immediately. Nevertheless, the result of a repeat CSF study after 5 days target treatment was negative for trophozoites and his vital signs became relatively stable with normal temperature, pulse, and pressure; yet the analysis of Glasgow coma scale (GCS) continually showed 3 points and no spontaneous breathing was detected. Considering the prognosis, the patient was transferred to a local hospital in Shenzhen on 30 August, he died on 3 September.

**DISCUSSION**

Since the first case of PAM was described by Fowler and Carter in Australia in 1965 [3], there have been nearly 200 cases reported hitherto, including 7 cases from China. Although *N. fowleri* is distributed worldwide, interestingly, a majority of
The fatality of PAM is extremely high with only 7 survivors to date [5]. This might be attributed to the following 2 reasons: Firstly, PAM is underdiagnosed since clinical symptoms are similar to those of other more commonly known types of meningitis [6]. Similar to this case, headache, fever, nausea, and vomiting are common clinical manifestations. The diagnosis of PAM is primarily based on the presence of trophozoites in the CSF that can be detected by trichrome or Giemsa stain. The time spent on diagnosis often results in delayed treatment. Most patients progress rapidly into a deep coma with significantly high intracranial pressure and CSF pressure before diagnosis, which can lead to death [7]. Secondly, there are no relevant clinical studies that have assessed the efficacy of a specific treatment option [5]. All the treatment methods, including the recommendation from The Centers for Disease Control and Prevention (CDC), are either based on case reports or in vitro studies. Presently, amphotericin B is accepted as the first choice drug for PAM. The *N. fowleri* is highly sensitive to amphotericin B in vitro [8], and all survivors from North America were reported to have received this medication [6,9,10]. In this case, the result of a repeat CSF study became negative for trophozoites after 5 days target treatment. The recommended therapy of CDC comprises of conventional amphotericin B administered intravenously at the dosages of 1.5 mg/kg/day in 2 doses for 3 days, followed by 1 mg/kg/day for an additional 11 days. The intrathecal administration of conventional amphotericin B (1.5 mg/day for 2 day and 1 mg/day for an additional 8 day) can also be used in combination with intravenous amphotericin B [11]. Other medications that could be potentially effective include fluconazole, miconazole, miltefosine, azithromycin, and rifampin, which are usually used in combination with conventional amphotericin B [5].

Although this fatal disease might be cured if treated early and effectively, most clinicians might have never encountered it before. Therefore, it is imperative for clinicians to have an awareness of the possibility of PAM in every case of purulent meningitis, especially in patients with recent freshwater exposure during the hot season.

**ACKNOWLEDGMENT**

This study was financially funded by the General Project Funds from the Health Department of Zhejiang Province. Grant No. 2015KYA018.

**REFERENCES**
